Funded Biotechnology Startups in Durham
Durham, North Carolina has generated at least 27 disclosed biotechnology funding rounds between March 2022 and August 2025, spanning deal sizes from $150K…
Durham, North Carolina has generated at least 27 disclosed biotechnology funding rounds between March 2022 and August 2025, spanning deal sizes from $150K (Verinetics, March 2024) to $150M (Atsena Therapeutics' Series C, April 2025). The largest transactions in this set are Atsena's round, G1 Therapeutics' $50M in November 2022, and Precision BioSciences' $40M in March 2024.
Round classification skews heavily toward "Series Unknown" or "Venture - Series Unknown" labels — together covering more than half the entries — reflecting the private or deal-by-deal structures common among clinical-stage companies. Named institutional rounds include four Series A closes, one Series B (Incyclix Bio, August 2025), one Series C, one Seed, one Corporate Round, and one Convertible Note. Lamassu Pharma raised twice within this window, with a $2M close in March 2024 followed by a $3M round in June 2025. One entry, Magnitude Biosciences, is headquartered in Durham, United Kingdom rather than Durham, North Carolina.
Most recent rounds
27 shownRelated listings
Frequently asked
What are the largest rounds in this Durham biotech dataset?
Atsena Therapeutics leads with a $150M Series C closed April 2, 2025. G1 Therapeutics raised $50M in November 2022, and Precision BioSciences closed a $40M round in March 2024. The next tier includes Xilis ($19M Series A, July 2022), Tavros Therapeutics ($18M Corporate Round, October 2022), and Ten63 Therapeutics ($16M Series A, May 2023).
How are funding stages distributed across these 27 companies?
Eleven rounds carry a "Series Unknown" label and four are classified "Venture - Series Unknown," together accounting for more than half the dataset. Named institutional stages include four Series A, one Series B (Incyclix Bio), one Series C (Atsena Therapeutics), one Seed (Magnitude Biosciences), one Corporate Round (Tavros Therapeutics), and one Convertible Note (GeneCentric Therapeutics). Three rounds — including Precision BioSciences' $40M close — show no stage classification at all.
Which companies have raised multiple rounds visible in this data?
Lamassu Pharma appears twice: a $2M round in March 2024 and a $3M Series Unknown in June 2025. No other company in the 27-row set shows a second distinct round entry.
Are there sub-$1M or early-stage companies worth flagging for outreach?
Verinetics raised $150K in March 2024, QATCH Technologies raised $250K in June 2023, and EydisBio closed a $500K round in October 2024. These sub-$1M amounts typically signal pre-institutional or grant-adjacent financing and indicate companies at the earliest discoverable stage of external funding.
Is all the activity here concentrated in Durham, North Carolina?
Twenty-six of the 27 entries are in Durham, North Carolina. Magnitude Biosciences, which raised an undisclosed Seed round in November 2022, is based in Durham, United Kingdom — likely appearing in the dataset due to the shared city name.
What is the most recent funding activity shown for Durham biotechs?
The newest entry is Incyclix Bio's $11M Series B, dated August 22, 2025. Before that, Lamassu Pharma raised $3M on June 3, 2025, and Atsena Therapeutics closed a $150M Series C on April 2, 2025.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.